Leita Ý frÚttum mbl.is

FDA SAMŮYKKIR REMDESIVIR TIL NOTKUNAR FYRIR UNGABÍRN OG UNG BÍRN.

The FDA Just Approved Remdesivir for Infants and Young Children

By Michelle Edwards April 27, 2022

https://uncoverdc.com/2022/04/27/the-fda-just-approved-remdesivir-for-infants-and-young-children/

á

Dr. Paul Marik Remdesivir Increases the Risk of Death

https://rumble.com/vtyh9w-dr.-paul-marik-remdesivir-increases-the-risk-of-death.html

Remdesivir Toxic Drug That Kills People Dr Paul Marik

Published December 19, 2021

https://rumble.com/vr2rcy-remdesivir-dr.-paul-marik-at-the-nashville-covid-summit.html

BandarÝska matvŠla- og lyfjaeftirliti­ (FDA) tilkynnti ß mßnudaginn um sam■ykki fyrir Veklury (Remdesivir) til a­ me­h÷ndla ungb÷rn 28 daga og eldri sem vega a­ minnsta kosti 7 pund sem hafa greinst me­ jßkvŠ­um ni­urst÷­um fyrir SARS-CoV-2á og eru anna­hvort l÷g­ inn ß sj˙krah˙s e­a eru me­ vŠgt e­a Ý me­allagi COVID-19 og eru Ý mikilli hŠttu ß a­ fara yfir Ý alvarlega COVID-19.

┴­ur en Veklury var sam■ykkt fyrir ungb÷rn og b÷rn var lyfi­ a­eins sam■ykkt til a­ me­h÷ndla „ßkve­na fullor­na“ og b÷rn 12 ßra og eldri sem vega a­ minnsta kosti 88 pund. A­ger­ gŠrdagsins, sem afturkalla­i ney­arnotkunarleyfi (EUA) sem ß­ur nß­i til ■essa barnahˇps, gerir lyfi­ a­ fyrstu sam■ykktu COVID-19 me­fer­inni fyrir b÷rn yngri en tˇlf ßra.

═ frÚttatilkynningu ˙tskřr­i FDA a­ hluti r÷kstu­ningsins fyrir sam■ykki Veklury fyrir ungb÷rn og ung b÷rn vŠri s˙ a­ ■a­ er engin ÷nnur „÷rugg og ßrangursrÝk me­fer­“, ■ar me­ tali­ COVID-19 tilrauna „bˇluefni­“ sem er n˙ ekki sam■ykkt fyrir b÷rn yngri en fimm ßra.

Patricia Cavazzoni, M.D., forst÷­uma­ur mi­st÷­var lyfjamats og rannsˇkna stofnunarinnar, sag­i:

„Ůar sem COVID-19 getur valdi­ alvarlegum veikindum hjß b÷rnum, ■ar sem sum ■eirra eru ekki me­ bˇlusetningarm÷guleika sem stendur, er ßfram ■÷rf ß ÷ruggum og ßhrifarÝkum me­fer­ar˙rrŠ­um fyrir COVID-19 fyrir ■ennan Ýb˙a. Sam■ykki dagsins ß fyrsta COVID-19 me­fer­arlyfinu fyrir ■ennan Ýb˙a sřnir skuldbindingu stofnunarinnar vi­ ■eirri ■÷rf.

FDA benti fljˇtt ß a­ Veklury, framleitt af Gilead Sciences, Inc., komi ekki Ý sta­inn fyrir „bˇlusetningu hjß einstaklingum sem mŠlt er me­ COVID-19 bˇlusetningu og ÷rvunarsk÷mmtum. Reyndar, "hvetur FDA almenning til a­ lßta bˇlusetja sig og fß ÷rvun ■egar ■a­ er gjaldgengt."

Dr. Paul Marik: Remdesivir eykur hŠttu ß dau­a!

Remdesivir sam■ykki hjß ungb÷rnum fylgir tilmŠlum WHO um lyf.

Sam■ykki Veklury hjß b÷rnum og ungb÷rnum kemur Ý kj÷lfar Gilead-tilkynningar 22. aprÝl 2022 um uppfŠrslur ß lei­beiningum Al■jˇ­aheilbrig­is mßlastofnunarinnar (WHO) Therapeutics and COVID-19: living guideline, sem mŠlir n˙ me­ Veklury til notkunar vi­ me­fer­ „sj˙klinga me­ ekki- alvarlegt COVID-19 Ý mestri hŠttu ß sj˙krah˙svist.

SamkvŠmt yfirlřsingu frß Gilead eru endursko­u­ tilmŠli WHO (fordŠmd af ritrřndum rannsˇknum og Al■jˇ­aheilbrig­isrß­inu) bygg­ar ß s÷nnunarg÷gnum fjßrm÷gnu­um af Gilead- 3. stigs tvÝblindri, lyfleysu-střr­ri klÝnÝskri rannsˇkn (PINETREE) sem sřna a­ ■riggja daga nßmskei­ af Veklury „drˇ verulega ˙r hŠttu ß sj˙krah˙svist fyrir sj˙klinga sem ekki eru ß sj˙krah˙si Ý hŠttu ß versnun.

Athyglisvert var a­ hlutar af yfirlřstum markmi­um rannsˇknarbˇkunarinnar frß 4. jan˙ar 2021, h÷nnun, vi­mi­um, upprunag÷gnum, blindun, mati, vi­mi­um um st÷­vun, greiningarmarkmi­, aukaendapunkta, lokagreiningu og vi­auka fyrir klÝnÝska rannsˇknina ß Remdesivir haf­i veri­ eytt.

S÷mulei­is, 12. ßg˙st 2021, T÷lfrŠ­igreiningarߊtlun fyrir klÝnÝsku rannsˇknina - sem var hŠtt vegna hagkvŠmni vi­ innritun Ý rannsˇkn og breyttar ■arfir ■ßtttakenda sem ekki voru ß sj˙krah˙sum - haf­i einnig verulegar ˙tfŠrslur ß 61 bla­sÝ­u sinni.

Ůegar tilkynnt var um lok klÝnÝsku rannsˇknarinnar sag­i tekjudrifna stofnuniná Gilead a­ Veklury vŠri ßfram sta­all Ý um÷nnun fyrir me­fer­ fullor­inna sj˙klinga ß sj˙krah˙si me­ COVID-19. SamkvŠmt lyfjafyrirtŠkinu er meira en helmingur allra innlagna sj˙klinga me­ COVID-19 Ý BandarÝkjunum me­h÷ndla­ir me­ Veklury. Samt sem ß­ur, sÝ­an Dr. Anthony Fauci ■rřsti upphaflega ß notkun lyfsins, hafa margir gagnrřnt 3.120 dala ver­mi­a lyfsins fyrir hverja me­fer­.

┴kv÷r­un FDA um a­ sam■ykkja Remdesivir fyrir um÷nnun barna

FDA heldur ■vÝ fram a­ ßkv÷r­un sÝn um a­ sam■ykkja Veklury hjß ungb÷rnum og ungum b÷rnum Ý AmerÝku sÚ studd af virkni vni­urst÷­um Ý ßframhaldandi National Institute of Allergy and Infectious Diseases (NIAID) styrktar af Gilead 3 stigsá rannsˇknum ß fullor­num.

A­ auki vÝsar stofnunin til Gilead-styrktar 2/3 stigs einarma, opinni klÝnÝskri rannsˇkn ß 53 b÷rnum sem fengu lyfi­ Ý allt a­ tÝu daga. Ůrßtt fyrir a­ engar rannsˇknar ni­urst÷­ur sÚu birtar fyrir klÝnÝsku rannsˇknina sem notu­ var til a­ sam■ykkja Veklury fyrir ungb÷rn og ung b÷rn - ߊtla­ur lokadagur er febr˙ar 2023 - tekur FDA fram a­ "÷ryggis- og lyfjahvarfafrŠ­ilegar ni­urst÷­ur ˙r fasa 2/3 rannsˇkninni ß b÷rnum voru svipa­ og hjß fullor­num." Remdesivir sam■ykki hjß ungb÷rnum fylgir tilmŠlum WHO um lyf.

Sam■ykki Veklury hjß b÷rnum og ungum b÷rnum kemur Ý kj÷lfar Gilead-tilkynningar 22. aprÝl 2022 um uppfŠrslur ß lei­beiningum Al■jˇ­aheilbrig­ismßlastofnunarinnar (WHO) Therapeutics and COVID-19: living guideline, sem mŠlir n˙ me­ Veklury til notkunar vi­ me­fer­ „sj˙klinga me­ ekki- alvarlegt COVID-19 Ý mestri hŠttu ß sj˙krah˙svist."

SamkvŠmt yfirlřsingu frß Gilead eru endursko­u­ tilmŠli WHO (fordŠmd af ritrřndum rannsˇknum og Al■jˇ­aheilbrig­isrß­inu) bygg­ar ß s÷nnunarg÷gnum ˙r Gilead-styrktri 3. stigs tvÝblindri, lyfleysu-střr­ri klÝnÝskri rannsˇkn (PINETREE) sem sřna fram ß ■a­.

Ůegar tilkynnt var um lok klÝnÝsku rannsˇknarinnar sag­i tekjudrifni Gilead a­ Veklury vŠri ßfram sta­all Ý um÷nnun fyrir me­fer­ fullor­inna sj˙klinga ß sj˙krah˙si me­ COVID-19.

áSamkvŠmt lyfjafyrirtŠkinu er meira en helmingur allra innlagna sj˙klinga me­ COVID-19 Ý BandarÝkjunum me­h÷ndla­ir me­ Veklury. Samt sem ß­ur, sÝ­an Dr. Anthony Fauci ■rřsti ß notkun lyfsins, hafa margir gagnrřnt 3.120 dala ver­mi­a lyfsins fyrir hvert me­fer­arnßmskei­.

┴kv÷r­un FDA um a­ sam■ykkja Remdesivir fyrir um÷nnun barna FDA heldur ■vÝ fram a­ ßkv÷r­un sÝna um a­ sam■ykkja Veklury hjß ungb÷rnum og ungum b÷rnum Ý AmerÝku sÚ studd af virknini­urst÷­um Ý ßframhaldandi National Institute of Allergy and Infectious Diseases (NIAID) styrktar stigs 3 rannsˇknum ß fullor­num.

A­ auki vÝsar stofnunin til Gilead-styrktar 2/3 stigs einarma, opinni klÝnÝskri rannsˇkn ß 53 b÷rnum sem fengu lyfi­ Ý allt a­ tÝu daga. Ůrßtt fyrir a­ engar rannsˇknarni­urst÷­ur sÚu birtar fyrir klÝnÝsku rannsˇknina sem notu­ var til a­ sam■ykkja Veklury fyrir ungb÷rn og ung b÷rn - ߊtla­ur lokadagur er febr˙ar 2023 - tekur FDA fram a­ "÷ryggis- og lyfjahvarfafrŠ­ilegar ni­urst÷­ur ˙r fasa 2/3 rannsˇkninni ß b÷rnum voru svipa­ og hjß fullor­num."

FDA bendir ß a­ aukaverkanir af notkun Veklury geta fali­ Ý sÚr „auki­ magn lifrarensÝma, sem getur veri­ merki um lifrarska­a; og ofnŠmisvi­br÷g­, sem geta fali­ Ý sÚr breytingar ß blˇ­■rřstingi og hjartslŠtti, lßgt s˙refnismagn Ý blˇ­i, hiti, mŠ­i, hvŠsandi ÷ndun, ■roti (t.d. varir, Ý kringum augu, undir h˙­), ˙tbrot, ˇgle­i, svitamyndun e­a skjßlfti. ”

áVi­varandi ßhyggjur af Remdesivir. Fyrst og fremst, eins og TrialSiteNews greindi frß, hafa eftirlitsferlar sem stu­la a­ leyfisveitingu Remdesivirs til a­ me­h÷ndla COVID-19 veri­ gagnrřnt af fj÷lm÷rgum sÚrfrŠ­ingum Ý tv÷ ßr. ═ fyrstu NIAID-střr­u rannsˇknunum (ACTT-1) Ý upphafi heimsfaraldursins var loka markmi­i­ (a­ draga ˙r dau­sf÷llum) breytt undir lok rannsˇknarinnar ■egar ■eir nß­u ekki markmi­inu.

Ůess Ý sta­ minnka­i lyfi­ innlagnartÝmann Ý nokkra daga. Ůessi ni­ursta­a var notu­ sem r÷kstu­ningur fyrir upphaflegu EUA og sÝ­an formlegu sam■ykki FDA ßn rß­gjafarfundar. Eric Topol, ßberandi hjartalŠknir hjß Scripps Research Translational Institute og yfirlřstur stu­ningsma­ur COVID-19 „bˇlusetninga“, mˇtmŠlti sam■ykki FDA ß Remdesivir.

Topol vÝsa­i til leyfis Evrˇpusambandsins fyrir lyfinu a­eins einni viku ß­ur en neikvŠ­ar ni­urst÷­ur WHO samst÷­u ni­urst÷­ur komu fram, sag­i Topol:

„Ůetta er mj÷g, mj÷g slŠmt ˙tlit fyrir FDA, og samskiptin milli Gilead og ESB gera ■a­ enn verra.” Jafn afhj˙pandi, ■ann 15. j˙lÝ 2021, Ý „upprunalegri rannsˇkn“ sem ber titilinn „Samband Remdesivir me­fer­ar vi­ lifun og lengd sj˙krah˙sdvalar me­al bandarÝskra hermanna ß sj˙krah˙si me­ COVID-19,“ kom Ý ljˇs Ý JAMA rannsˇkn a­ „hef­bundin notkun Remdesivirs gŠti veri­ tengt aukinni notkun sj˙krar˙ma en ekki auknum lÝfsgŠ­um.“

Gilead er a­ grŠ­a milljar­a ß vafas÷mum COVID-me­fer­um. Gilead Sciences, sem uppskar gÝfurlegan hagna­ af COVID-19 svipa­ og stˇru lyfjarisarnir Pfizer og Moderna, greindi frß ˇtr˙legum 27,3 millj÷r­um dala Ý ßrslokatekjur fyrir ßri­ 2021, ßsamt s÷lu ß lyfinu Veklury (Remdesivir).

Ůann 1. febr˙ar birti lyfjaframlei­andinn uppgj÷r sitt fyrir fjˇr­a ßrsfjˇr­ung og 2021, og tilkynnti um 1,4 milljar­a dala s÷lu fyrir Veklury ß fjˇr­a ßrsfjˇr­ungi 2021, sem er um 30 prˇsent lŠkkun frß sama ßrsfjˇr­ungi 2020. Hins vegar, heilsßrstekjur fyrir Veklury nß­i 5,6 millj÷r­um dala ßri­ 2021, sem er 98 prˇsenta st÷kk frß tekjum 2020.

SamkvŠmt Gilead er Veklury „sala Ý nßnu samrŠmi vi­ ■rˇun COVID-19 sj˙krah˙svistar Ý BandarÝkjunum." Lyfjaframlei­andinn, sem er a­ vinna a­ Veklury inn÷ndunartŠki, sag­ist b˙ast vi­ a­ innlagnartÝ­ni lŠkki ßri­ 2022 en spßir samt 2 millj÷r­um dala Ý s÷lu Veklury ß ■essu ßri.

Dr. Paul Marik on Remdesivir at the 12/18 Nashville COVID Summit:

“Halfway through the study they did an interim analysis and found that the study was not going to be positive. So they changed the end point, the goal post, halfway through the study. That is called scientific misconduct.”

Remdesivir: The hospital gets a 20% bonus on the ENTIRE HOSPITAL BILL
https://rumble.com/vr2s81-remdesivir-dr.-paul-marik-the-hospital-gets-a-20-bonus-on-the-entire-hospit.html

Dr. Robert Malone: Before You Inject Your Child! All Parents Need To Hear This!

https://rumble.com/vqq7gc-dr.-robert-malone-before-you-inject-your-child.html

https://gettr.com/user/wethepeopleusa

https://mb.ntd.com/live-global-covid-summit-nashville-part-2_716402.html

LINKS.

https://uncoverdc.com/2022/02/15/scott-schara-pfizer-drugs-medical-malpractice-killed-his-daughter-grace/

Veklury« (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19

April 25, 2022 at 2:29 PM EDT

https://investors.gilead.com/news-releases/news-release-details/vekluryr-remdesivir-first-and-only-approved-treatment-pediatric

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines

https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-who-recommendation-of-veklury-remdesivir-and-acceleration-of-prequalification-submission

https://app.magicapp.org/#/guideline/nBkO1E/rec/nBMO8R

Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis

https://pubmed.ncbi.nlm.nih.gov/33301514/

https://worldcouncilforhealth.org/news/2022/04/remdesivir/70596/

https://clinicaltrials.gov/ct2/show/NCT04501952

https://uncoverdc.com/2022/04/27/the-fda-just-approved-remdesivir-for-infants-and-young-children/

https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-phase-3-veklury-remdesivir-study-in-high-risk-non-hospitalized-patients-with-covid-19

https://www.finance.senate.gov/ranking-members-news/wyden-grassley-sovaldi-investigation-finds-revenue-driven-pricing-strategy-behind-84-000-hepatitis-drug

Gilead's long-awaited remdesivir price is $3,120, in line with watchdog estimates

By Angus Liu Jun 29, 2020 01:50pm

https://www.fiercepharma.com/marketing/gilead-prices-covid-19-drug-remdesivir-line-cost-analysis

FDA Approves Use of Remdesivir for Children & Babies

https://www.trialsitenews.com/p/stevenarthur/fda-approves-use-of-remdesivir-for-children-babies-b9086b5a

https://uncoverdc.com/?s=remdesivir

The highly accomplished Dr. Paul Marik is the founder and Co-Chief Medical Officer at Front Line COVID-19 Critical Care Alliance (FLCCC) and long-time director of Sentara Norfolk General Hospital’s intensive care unit. He recently filed a lawsuit against Sentara Healthcare System because they refuse to let him treat his patients with the highly-effective drug Ivermectin, as well as other proven treatments in his established MATH+ Protocol

In 2020, Dr. Marik founded FLCCC along with several other critical care specialists to “gather, research and share information among health care professionals and the public.” The single purpose of their collaboration was to meet COVID-19 head-on and save lives. Indeed, by analyzing, devising, and publicizing best-practice treatments for the virus, Dr. Marik and his colleagues pioneered treatment protocols that have become standard of care. One such regimen is known as the MATH+ Protocol, which doctors worldwide use to treat COVID-19.

https://uncoverdc.com/2021/11/22/flccc-founder-dr-marik-awaits-court-decision-as-patients-die/

Fauci’s Emergency Teleconference: The Players

https://uncoverdc.com/2021/07/14/faucis-emergency-teleconference-the-players/

https://uncoverdc.com/2021/12/16/new-evidence-pfizer-covid-jab-more-harm-than-good/

https://uncoverdc.com/2021/05/31/vaccine-expert-warns-we-made-a-big-mistake/

Covid-19 Symposium 2021: Dr Byram Bridle, Viral Immunologist, University of Guelph

https://youtu.be/VrNQ8hkxHw8

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781959?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=071521

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-agreement-gilead-manufacture-remdesivir

https://www.beckershospitalreview.com/pharmacy/gilead-saw-5-6b-in-remdesivir-sales-last-year.html

ŮŢđAND AGNŢ


ź SÝ­asta fŠrsla | NŠsta fŠrsla

Athugasemdir

1 Smßmynd: KristÝn Inga Ůormar

Takk fyrir ■essa fŠrslu, ■etta allt er ekkert anna­ en skelfilegt!

KristÝn Inga Ůormar, 3.5.2022 kl. 23:07

2 Smßmynd: Agnř

Jß ■a­ er ■a­á svo sannarlega rosalegt nafna..Og takk fyrir a­ lesa bloggi­ mitt 👍

Agnř, 4.5.2022 kl. 11:05

BŠta vi­ athugasemd

Hver er summan af sex og nÝu?
Nota HTML-ham

Nota bene

Translate your website into 52 languages

We The People Will Not Be Chipped!

NO VERICHIP INSIDE ME! I WILL NOT BE MARKED AS I WERE A BEAST!

We The People Will Not Be Chipped!
http://www.wethepeoplewillnotbechipped.com/main/news.php
We The People Will Not Be Chipped!

Höfundur

Agný
Agný

Betra er að vita "lítið" en um "mikið", frekar en að vita mikið um lítið... 

agnyrose@gmail.com

CHEMTRAILS OR?/EFNARÁKIR EÐA?

http://www.flickr.com/photos/32781077@N02/show/

Chemtrail-Related Illnesses  SJÚKDÓMSEINKENNI TENGD EFNARÁKUM

http://globalskywatch.com 

"Better to know little about a lot..than lot about one thing"

"Betra að vita lítið en um mikið...heldur en mikið um lítið.. "

Bloggvinir

Nřjustu myndir

  • https  bucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com public images 9fc4e144-1976-445f-9505-142c462106fc 800x577
  • 12717675 10207211077647579 3269554484766683045 n
  • Inga-2
  • Inga-2
  • ...19_131709-1

Nřjustu myndb÷ndin

Bólusetningarþvingun

JFK  /  BUSH

Capitalist_Conspriracy

911  A  CLOSER  LOOK

THE HIDDEN HISTORY OF 9-11-2001: Prof. Paul Zarembka

Innskrßning

Ath. Vinsamlegast kveiki­ ß Javascript til a­ hefja innskrßningu.

Haf­u samband